Overview

Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with Type 2 Diabetes (T2D).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Glimepiride
Metformin
Vildagliptin